WW International (WeightWatchers)
WW runs weight loss coaching and GLP-1 prescribing after emerging from bankruptcy in 2025.
On the record
Checkpoint: FDA peptide and compounding decision that could reshape the telehealth GLP-1 field
The call
WW survived bankruptcy but its old coaching business is fading while its new drug-reselling business looks like every other telehealth GLP-1 shop, with no CEO yet to decide what comes next.
WeightWatchers built its business on a points system and online community to help people lose weight, but now faces two problems: AI chatbots like ChatGPT can give diet advice for free, and prescription weight loss drugs like Ozempic work so well that drug makers and telehealth companies like Hims are selling them directly to patients without needing WW's help. WW tried to pivot by offering these drugs too, but it is just reselling what Novo Nordisk and Eli Lilly make, competing on price and convenience against companies that are much bigger and own the drugs themselves. The real turning point will be whether WW can keep its newer clinical customers (people buying the drug service) growing faster than it loses its old diet community customers, and whether a new CEO can convince investors there is still a winning strategy here or if the company is just slowly running out of cash.
Why
01
AI pressure: ChatGPT and similar chat assistants. Free AI chat gives diet and habit coaching that used to cost a WW subscription, hollowing out the behavioral business. Could AI do the core job? Only partly.
02
Bigger players: Novo Nordisk and Eli Lilly selling GLP-1 drugs direct to consumers. Novo's direct-to-consumer Ozempic pill launching May 2026 lets patients skip WW and get the drug straight from the maker. Could a giant copy it? Yes, easily.
03
What protects it. A menopause and perimenopause clinical program with early payer interest, if exclusive contracts and published outcomes actually materialize.
What would change this call
Whether WW names a permanent CEO by late 2026. A prolonged vacancy would signal continued drift rather than a coherent clinical strategy.
Q2/Q3 2026 earnings showing Clinical subscriber growth rate versus prior 46% YoY pace. Deceleration would show Novo's direct-to-consumer Ozempic pill and rivals are eroding WW's clinical growth.
Whether behavioral subscriber decline (−26% YoY) narrows or worsens in 2026 filings. Continued acceleration of losses would confirm the legacy coaching business is being abandoned by customers.
Q2/Q3 2026 earnings showing Clinical subscriber growth rate versus prior 46% YoY pace. Deceleration would show Novo's direct-to-consumer Ozempic pill and rivals are eroding WW's clinical growth.
Whether behavioral subscriber decline (−26% YoY) narrows or worsens in 2026 filings. Continued acceleration of losses would confirm the legacy coaching business is being abandoned by customers.
Key numbers
- Revenue $710.6M FY2025, down 9.6% YoY
- Behavioral subscribers down 26% YoY to 2.45M
- Clinical subscribers up 46% YoY to 197,000
Named risks
- No permanent CEO since March 2026 amid strategic pivot and board departures.
- Behavioral subscriber base declining 26% YoY erodes legacy revenue faster than Clinical can offset.
- Cash fell from $160M to $121M in one quarter while carrying $465M in term-loan debt.
- Clinical/GLP-1 segment is a pass-through reseller model with no differentiation versus larger telehealth rivals.
- Drugmakers Novo Nordisk and Lilly increasingly selling GLP-1s direct to consumer, bypassing telehealth intermediaries like WW.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Novo Nordisk / Eli Lilly | losing to | Control ~95% of branded GLP-1 revenue and now sell direct to consumers, oral Ozempic launched May 2026 |
| Hims & Hers | losing to | 3x WW's size at $2.35B FY2025 revenue, Q1 2026 revenue $608.1M despite growth slowdown to 3.8% YoY |
| ChatGPT / AI assistants | losing to | WW embedded its app inside ChatGPT Feb 2026 rather than compete on free nutrition guidance |
| Noom | contesting | Noom Med bundles GLP-1 telehealth with coaching at $149-209/month, comparable to WW's Med+ |
| Ro, Sesame, GoodRx Care | contesting | Multiple telehealth GLP-1 rivals priced $19.99-149/month competing in WW's growth segment |
Questions people ask
- Is WeightWatchers profitable in 2026?
- WW guided FY2026 revenue of $620M-$635M with Adjusted EBITDA of $105M-$115M (reaffirmed May 7, 2026), but Q4 2025 posted a $6M net loss and cash fell from $160M to $121M by Q1 2026, showing thin, pressured profitability.
- Who owns WeightWatchers now?
- After WW's prepackaged Chapter 11 (filed May 6, 2025, emerged June 24, 2025), former lenders and noteholders received 91% of new common equity plus $465M in new term loans, while pre-petition shareholders retained just 9%.
- Can AI replace WeightWatchers' coaching?
- Much of it already is: WW's Sierra-powered AI agent contained about 70% of customer service cases without a human within its first week (Feb 2024), and WW launched an app inside ChatGPT in February 2026 rather than compete against free AI nutrition guidance.
- Who is WeightWatchers' biggest competitor?
- Hims & Hers, roughly 3x WW's size with $2.35B FY2025 revenue and a Novo Nordisk branded-drug partnership, alongside Novo Nordisk and Eli Lilly themselves, who control about 95% of branded GLP-1 revenue and now sell directly to consumers (Novo's oral Ozempic launched May 2026).
- Is WeightWatchers shrinking or growing?
- Overall revenue is shrinking, $710.6M in FY2025 (down 9.6% YoY) with FY2026 guidance of $620M-$635M, but Clinical/GLP-1 subscription revenue grew 44.7% in FY2025 and Clinical subscribers rose 46% YoY to 197,000 by Q1 2026.
- Did WeightWatchers go bankrupt?
- Yes, WW filed a prepackaged Chapter 11 on May 6, 2025 and emerged June 24, 2025 after eliminating about $1.15 billion of roughly $1.6 billion in debt, restructuring its capital base but diluting legacy shareholders to 9% ownership.
Timeline
- 2026-05-01Med+ expanded to include newly launched oral Ozempic pill
- 2026-04-27Announced use of up to $40M cash to prepay term-loan debt by up to $42M
- 2026-04-03Leadership transition: interim CEO tenure ends, Office of the CEO formed, two board resignations
- 2026-03-31Q1 2026 results: revenue $168M, Clinical subscribers 197,000 (+46% YoY)
- 2026-03-05CEO Sima Sistani steps down; stock falls, down over 90% YTD
- 2026-02-26WeightWatchers app launches inside ChatGPT ecosystem
- 2025-12-26Global rollout of Med+ program and AI body scanner
- 2025-06-24WW emerges from Chapter 11, debt cut by $1.15B, lenders take 91% equity
- 2025-05-06WW files prepackaged Chapter 11 bankruptcy
- 2023-04-30WW acquires telehealth platform Sequence for $106-132M, becomes WeightWatchers Clinic
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- $1.15B Debt Cut (2026-06-16)
- WeightWatchers Completes Financial Reorganization (2025-06-25)
- Weight Watchers (WW) Q4 2025 Summary (2026-07-13)
- EX-99.1
- EX-99.1
- WW International Earnings (2026-07-13)
- Weight Watchers Report Finds Integrated GLP-1 Support (2026-03-11)
- Weight Watchers Prepackaged Chapter 11 (2025-12-05)
- Weight Watchers Number of Employees 2026 (2026-06-29)
- Weight Watchers - Headcount, Funding & Open Jobs (2026-06-26)
- Sequence Pricing Analysis (2026-05-25)
- WeightWatchers Unveils Next-Gen Program (2024-12-10)